A recurrent de novo damaging variant in EMP2 causes progressive symmetric erythrokeratoderma
Open Access
- 4 August 2025
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (32)
Abstract
Genetic investigation in Mendelian skin disorders featuring generalized or localized skin scaling and redness, known as the ichthyoses, has revealed novel pathways relevant to epidermal integrity, barrier function, and desquamation. Here, we show that a recurrent de novo missense variant in EMP2 (epithelial membrane protein 2), which encodes a cell surface tetraspan protein in the growth-arrest specific 3 (GAS3)/peripheral myelin protein 22 (PMP22) family, is associated with a Mendelian skin disorder in the progressive symmetric erythrokeratoderma spectrum. The disorder features severely thickened, red, and scaly skin at sites of wound healing or repetitive movement including on the face, genitals, flexural areas, and the palms and soles. EMP2 has previously been shown to directly associate with focal adhesion kinase, which links cell junction forces to signaling pathways relevant to proliferation, migration, and wound healing. Using single-cell spatial transcriptomics in affected tissue, we found ectopic suprabasal activation of signaling pathways downstream of receptor tyrosine kinases including epidermal growth factor receptor (EGFR), which we confirmed with western blotting in affected cells, supporting a gain-of-function mechanism for mutant EMP2. Remarkably, treatment with erlotinib, an EGFR inhibitor, led to marked clinical improvement underscoring the key role of EMP2 in epidermal differentiation and proliferation.Keywords
Funding Information
- HHS | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR068392)
- HHS | NIH | National Human Genome Research Institute (5U54HG006504)
- HHS | NIH | National Institute of General Medical Sciences (T32GM136651)
This publication has 68 references indexed in Scilit:
- Epithelial membrane protein 2 (EMP2): A systematic review of its implications in pathogenesisActa Histochemica, 2022
- The Genomic and Phenotypic Landscape of IchthyosisJAMA Dermatology, 2021
- Gene Set Knowledge Discovery with EnrichrCurrent Protocols, 2021
- Use of Epidermal Growth Factor Receptor Inhibitor Erlotinib to Treat Palmoplantar Keratoderma in Patients With Olmsted Syndrome Caused by TRPV3 MutationsJAMA Dermatology, 2020
- Targeted Inhibition of the Epidermal Growth Factor Receptor and Mammalian Target of Rapamycin Signaling Pathways in Olmsted SyndromeJAMA Dermatology, 2020
- Quantitative Ultrasensitive Bright-Field RNA In Situ Hybridization with RNAscope2014
- Expanding the Clinical Phenotype Associated WithELOVL4MutationJAMA Neurology, 2014
- The PMP22 Gene and Its Related DiseasesMolecular Neurobiology, 2012
- Positron Emission Tomography Imaging of Endometrial Cancer Using Engineered Anti-EMP2 Antibody FragmentsMolecular Imaging and Biology, 2012
- The missense mutation G12D in connexin30.3 can cause both erythrokeratodermia variabilis of Mendes da Costa and progressive symmetric erythrokeratodermia of GottronAmerican Journal of Medical Genetics Part A, 2009